These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2106690)

  • 41. von Willebrand's Disease.
    Zimmerman TS; Ruggeri ZM
    Clin Haematol; 1983 Feb; 12(1):175-200. PubMed ID: 6404576
    [No Abstract]   [Full Text] [Related]  

  • 42. Von Willebrand's disease.
    Br Med J; 1976 Sep; 2(6038):715-6. PubMed ID: 1086116
    [No Abstract]   [Full Text] [Related]  

  • 43. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
    Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
    J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitreous, retinal and subretinal hemorrhages associated with von Willebrand's syndrome.
    Shiono T; Abe S; Watabe T; Noro M; Tamai M; Akutsu Y; Ishikawa M; Suzuki S; Mori K
    Graefes Arch Clin Exp Ophthalmol; 1992; 230(5):496-7. PubMed ID: 1521819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.
    Bergamaschini L; Mannucci PM; Federici AB; Coppola R; Guzzoni S; Agostoni A
    J Lab Clin Med; 1995 Mar; 125(3):348-55. PubMed ID: 7897302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current therapy in children and adolescents with von Willebrand disease.
    Buga-Corbu I; Arion C
    J Med Life; 2014 Jun; 7(2):264-9. PubMed ID: 25408737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor.
    Mannucci PM; Tamaro G; Narchi G; Candotti G; Federici A; Altieri D; Tedesco F
    Eur J Haematol; 1987 Nov; 39(5):467-70. PubMed ID: 3121382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged post-operative bleeding due to an acquired von Willebrand syndrome.
    Kinsey SE; Ryder KO; Machin SJ
    Postgrad Med J; 1987 Oct; 63(744):901-2. PubMed ID: 3128779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.
    van Genderen PJ; Michiels JJ; Bakker JJ; van 't Veer MB
    Vox Sang; 1994; 67(1):14-7. PubMed ID: 7975445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. von Willebrand's disease. Pathogenesis and clinical aspects.
    Lethagen S
    Crit Rev Oncol Hematol; 1993 Aug; 15(1):1-11. PubMed ID: 8240703
    [No Abstract]   [Full Text] [Related]  

  • 51. Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor.
    Casonato A; Pontara E; Sartorello F; Gemmati D; Cattini MG; Girolami A
    Haematologica; 2001 Oct; 86(10):1110-1. PubMed ID: 11602423
    [No Abstract]   [Full Text] [Related]  

  • 52. Venous thromboembolism in von Willebrand disease.
    Mannucci PM
    Thromb Haemost; 2002 Sep; 88(3):378-9. PubMed ID: 12353063
    [No Abstract]   [Full Text] [Related]  

  • 53. von Willebrand factor: the new treatment paradigm--introduction.
    Lee CA; Montgomery RR
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S1-2. PubMed ID: 15849520
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of Haemate-P as prophylaxis of recurrent bleeding in a patient with type 2B von Willebrand's disease.
    Franchini M; Giuffrida A; Gandini G
    Blood Coagul Fibrinolysis; 2005 Nov; 16(8):571-2. PubMed ID: 16269931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 56. Hemophilia A and von Willebrand deficiency: therapeutic implications.
    Basso M; Lazzareschi I; Curatola A; Di Gennaro L; Buonsenso D; Gatto A; De Candia E; De Cristofaro R
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):397-401. PubMed ID: 32255574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are thrombotic complications in patients with von Willebrand's disease expression of a multifactorial disease?
    Franchini M; Salvagno GL; Manzato F; Lippi G
    Haematologica; 2005 Nov; 90 Suppl():ECR34. PubMed ID: 16266925
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical use of Haemate-P in inherited von Willebrand's disease: a patient with type 3 VWD and recurrent menometrorrhagia.
    Dolatkhah R; Kermani IA; Sanaat Z; Seifi S; Ziaei JE; Nikanfar A; Esfehani A; Chavoushi SH
    Haemophilia; 2010 May; 16(3):555-7. PubMed ID: 20059558
    [No Abstract]   [Full Text] [Related]  

  • 59. von Willebrand's disease: a report from a meeting in the Åland islands.
    Berntorp E; Peake I; Budde U; Laffan M; Montgomery R; Windyga J; Goodeve A; Petrini P; von Depka M; Miesbach W; Lillicrap D; Federici AB; Lassila R; White G
    Haemophilia; 2012 Sep; 18 Suppl 6(0 6):1-13. PubMed ID: 22906074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Von Willebrand's disease associated with intermittent thrombocytopenia.
    Nielsen EG; Svejgaard A
    Lancet; 1967 Nov; 2(7523):966-8. PubMed ID: 4167520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.